Otrivin with menthol and eucalyptus nasal spray dosed 0.1% bottle 10 ml with sprayer

Otrivin with menthol and eucalyptus is a decongestant for topical use in diseases of the nasal cavity.

Xylometazoline, when applied nasally, causes constriction of the blood vessels of the nasal mucosa and adjacent areas of the nasopharynx, thus eliminating edema and hyperemia of the nasal and nasopharynx mucosa, and also reduces the associated increased mucus secretion and facilitates the removal of blocked secretions from the nose and passages and facilitates nasal breathing.

It is used for symptomatic treatment of nasal congestion in colds, hay fever, other allergic rhinitis, sinusitis. To facilitate the outflow of secretions in diseases of the paranasal sinuses. Adjunctive therapy in cases of otitis media (to eliminate swelling of the mucous membrane). To facilitate rhinoscopy.

When applied topically, the drug is practically not absorbed, and the concentrations of xylometazoline in blood plasma are so low that they are practically undetectable (the plasma concentration is close to the detection limit).

• active ingredient: xylometazoline hydrochloride;
• 1 ml of solution contains xylometazoline hydrochloride 1 mg;
• Excipients: sodium dihydrogen phosphate, dihydrate; sodium hydrogen phosphate, dodecahydrate; sodium chloride; benzalkonium chloride; disodium edetate; menthol; eucalyptol; sorbitol (E 420); polyethoxylated hydrogenated castor oil; purified water.

Hypersensitivity to xylometazoline or any other component of the drug, angle-closure glaucoma, transsphenoidal hypophysectomy and transnasal or transoral surgical interventions with exposure of the meninges or their presence in history, dry rhinitis (rhinitis sicca) or atrophic rhinitis.

It should be prescribed with caution to patients with cardiovascular diseases, arterial hypertension, diabetes mellitus, hyperthyroidism, pheochromocytoma, prostatic hypertrophy, and should not be used in patients receiving concomitant treatment with MAO inhibitors and.

The drug should be used by adults and children over 12 years of age, 1 injection into each nasal passage up to 3 times a day. Apply no more than 3 times in each nasal passage per day. The duration of treatment depends on the course of the disease and should not exceed 7 consecutive days.

Do not cut off the tip of the spray. The nasal spray is metered and ready to use.

The metered spray ensures accurate dosing and proper distribution of the solution over the surface of the nasal mucosa. Each injection delivers 0.14 ml of solution, which corresponds to 0.14 mg of xylometazoline.

Before use, prime the dosing device by pumping it several times until the spray starts to come out into the air. The dosing device will be ready for immediate use the next time it is used.

Before first use, prime the spray by pressing the spray 4 times. The spray will then be ready for use throughout the treatment period. If the spray does not spray when the spray is pressed or the product has not been used for more than 7 days, the spray should be primed again by pressing 4 times into the air.

The spray should be applied as follows:

• Clean your nose thoroughly before using the drug;
• The bottle should be held vertically, supporting the bottom with your thumb and placing the tip between two fingers;
• tilt the bottle slightly and insert the tip into the nostril;
• inject and simultaneously take a light breath through your nose;
• after use, clean and dry the tip before replacing the cap;
• To prevent infection, each vial of the drug can only be used by one person.

The last application is recommended immediately before bedtime.

The drug should not be used for longer than 7 consecutive days, as prolonged or excessive use may lead to the development of rhinitis medicamentosa, which consists in the recurrence of nasal congestion, i.e. symptoms similar to a runny nose, and/or atrophy of the nasal mucosa.

The recommended dose of the drug should not be exceeded, especially when treating children and the elderly.

Use during pregnancy or breastfeeding

The drug should not be used during pregnancy due to its potential vasoconstrictor effect.

There is no evidence of any adverse effects on the infant. It is not known whether xylometazoline is excreted in breast milk, therefore caution is required and the drug should be used during breastfeeding only as directed by a physician.

Children

The drug should not be used in children under 12 years of age.

Ability to influence reaction speed when driving vehicles or other mechanisms

The drug usually has no or negligible influence on the ability to drive or use machines. With prolonged use of the drug or in high doses, its effect on the cardiovascular system cannot be ruled out.

Excessive topical application of xylometazoline hydrochloride or accidental ingestion may result in severe dizziness, sweating, a significant decrease in body temperature, headache, bradycardia, arterial hypertension, respiratory depression, coma and convulsions. Elevated blood pressure may change to low blood pressure. Young children are more sensitive to toxic effects than adults.

All patients with suspected overdose should receive appropriate supportive measures and, if necessary, immediate symptomatic treatment under medical supervision. Medical care should include observation of the patient for several hours. In the case of severe overdose accompanied by cardiac arrest, resuscitation measures should last at least 1 hour.

Immune system disorders: rare (<1/10,000): hypersensitivity reactions, including angioedema, rash, itching.

Nervous system disorders: common (<1/100, <1/10): headache.

On the part of the organs of vision: rare (<1/10,000): temporary visual impairment.

Cardiovascular system: rare (<1/10,000): irregular or rapid heartbeat, arterial hypertension, arrhythmia.

Respiratory, thoracic and mediastinal disorders: common (<1/100, <1/10): dryness or discomfort of the nasal mucosa, burning sensation; rhinitis medicamentosa.

Gastrointestinal system: common (<1/100, <1/10): nausea.

General disorders and administration site conditions: common (<1/100, <1/10): burning sensation at the application site.